Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
KaNDy Therapeutics logo — KaNDy Therapeutics develops NT-814 for treating female hormo...

KaNDy Therapeutics

KaNDy Therapeutics develops NT-814 for treating female hormone-related conditions, with the primary focus on menopause.

Founded 2017 United Kingdom Stevenage, United Kingdom 2-10 employees Series C Total: $25.00M Biotechnology, Health Care +1

General Information

Company Name KaNDy Therapeutics
Founded Year 2017
Location United Kingdom Stevenage, United Kingdom
Employees 2-10
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with KaNDy Therapeutics. To contact KaNDy Therapeutics, visit kandytherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About KaNDy Therapeutics

KaNDy Therapeutics, founded in 2017, prioritizes the development of NT-814 to address prevalent female sex-hormone linked disorders, specifically targeting menopause-related symptoms. The company's last investment of £25.00M in Series C funding on 29 August 2018 garnered support from a notable consortium of investors including Advent Life Sciences, Longitude Capital, Forbion, OrbiMed, and Fountain Healthcare Partners. Operating from the United Kingdom, KaNDy Therapeutics positions itself within the Biotechnology, Health Care, and Health and Wellness industries, holding potential for impactful advancements in the treatment of female hormone-related conditions. As a clinical stage entity, the focus on improving patients' quality of life exhibits strategic alignment with the market demand for innovative menopause management solutions.

Taxonomy: therapeutics, female health, menopause, hormone-related conditions, clinical stage development, non-hormonal therapy, post-menopausal symptoms, bio-technical research, treatment, vasomotor symptoms

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series C £25.00M 5
Advent Life Sciences Longitude Capital Forbion
Advent Life Sciences, Longitude Capital +3
29 Aug 2018

KaNDy Therapeutics Alternatives & Competitors

View All Alternatives
KaNDy Therapeutics vs
Palatin Technologies
Palatin Technologies

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune cond...

Post-IPO Equity
50 employees
Biotechnology, Health Care
KaNDy Therapeutics vs
Trimel Pharmaceuticals
Trimel Pharmaceuticals

Pioneering innovative solutions for male hypogonadism, female sexual dysfunction, and respiratory di...

Post-IPO Equity
Biotechnology, Health Care
KaNDy Therapeutics vs
BioSante Pharmaceuticals
BioSante Pharmaceuticals

Pioneering advancements in female sexual health, menopause, contraception, and male hypogonadism wit...

Post-IPO Equity
Biotechnology, Health Care
View all alternatives

FAQ About KaNDy Therapeutics

KaNDy Therapeutics develops NT-814 for treating female hormone-related conditions, with the primary focus on menopause.
KaNDy Therapeutics was founded in 2017.
KaNDy Therapeutics is headquartered in Stevenage, United Kingdom.
KaNDy Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on therapeutics, female health, menopause and hormone-related conditions.
KaNDy Therapeutics has approximately 2-10 employees.
KaNDy Therapeutics has completed 1 funding round, raising a total of $25.00M. The latest funding stage is Series C.
Top alternatives and competitors to KaNDy Therapeutics include Palatin Technologies, Trimel Pharmaceuticals, BioSante Pharmaceuticals, The Healthy Choice Compounding Pharmacy, Lumos Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
KaNDy Therapeutics and Palatin Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for KaNDy Therapeutics, https://bouncewatch.com/company/kandy-therapeutics, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes